A myristoyl amide derivative of doxycycline potently targets cancer stem cells (CSCs) and prevents metastasis, without retaining antibiotic activity

Ozsvari, B, Magalhaes, LG, Latimer, J ORCID: https://orcid.org/0000-0001-9704-0209, Kangasmetsa, J, Sotgia, F ORCID: https://orcid.org/0000-0003-2826-4529 and Lisanti, MP ORCID: https://orcid.org/0000-0003-2034-1382 2020, 'A myristoyl amide derivative of doxycycline potently targets cancer stem cells (CSCs) and prevents metastasis, without retaining antibiotic activity' , Frontiers in Oncology, 10 , p. 1528.

PDF - Published Version
Available under License Creative Commons Attribution 4.0.

Download (10MB) | Preview
[img] PDF - Accepted Version
Restricted to Repository staff only

Download (263kB)


Here, we describe the chemical synthesis and biological activity of a new Doxycycline derivative, designed specifically to more effectively target cancer stem cells (CSCs). In this analogue, a myristic acid (14 carbon) moiety is covalently attached to the free amino group of 9-amino-Doxycycline. First, we determined the IC50 of Doxy-Myr using the 3D-mammosphere assay, to assess its ability to inhibit the anchorage-independent growth of breast CSCs, using MCF7 cells as a model system. Our results indicate that Doxy-Myr is >5-fold more potent than Doxycycline, as it appears to be better retained in cells, within a peri-nuclear membranous compartment. Moreover, Doxy-Myr did not affect the viability of the total MCF7 cancer cell population or normal fibroblasts grown as 2D-monolayers, showing remarkable selectivity for CSCs. Using both gram-negative and gram-positive bacterial strains, we also demonstrated that Doxy-Myr did not show antibiotic activity, against Escherichia coli and Staphylococcus aureus. Interestingly, other complementary Doxycycline amide derivatives, with longer (16 carbon; palmitic acid) or shorter (12 carbon; lauric acid) fatty acid chain lengths, were both less potent than Doxy-Myr for the targeting of CSCs. Finally, using MDA-MB-231 cells, we also demonstrate that Doxy-Myr has no appreciable effect on tumor growth, but potently inhibits tumor cell metastasis in vivo, with little or no toxicity. In summary, by using 9-amino-Doxycycline as a scaffold, here we have developed new chemical entities for their further development as anti-cancer agents. These compounds selectively target CSCs, e.g., Doxy-Myr, while effectively minimizing the risk of driving antibiotic resistance. Taken together, our current studies provide proof-of-principle, that existing FDA-approved drugs can be further modified and optimized, to successfully target the anchorage-independent growth of CSCs and the process of tumor cell metastasis. Based on these findings, we propose that it may be more appropriate to refer to tumor-spheres as metasta-spheres, to better reflect the close relationship between 3D anchorage-independent growth and metastasis.

Item Type: Article
Schools: Schools > School of Environment and Life Sciences
Journal or Publication Title: Frontiers in Oncology
Publisher: Frontiers Media
ISSN: 2234-943X
Related URLs:
Funders: Lunella Biotech, Inc.
Depositing User: USIR Admin
Date Deposited: 29 Jul 2020 08:54
Last Modified: 16 Feb 2022 05:12
URI: https://usir.salford.ac.uk/id/eprint/57737

Actions (login required)

Edit record (repository staff only) Edit record (repository staff only)


Downloads per month over past year